Effect of Extended-Release NiacinLaropiprant Combination on Plasma Adiponectin and Insulin Resistance in Chinese Patients with Dyslipidaemia

Abstract EN

Objectives.

This study examined whether the increase of adiponectin associated with extended-release (ER) niacin/laropiprant combination attenuates the adverse effect of niacin on glucose and insulin resistance in Hong Kong Chinese patients with dyslipidaemia.

Methods.

Patients ( N = 121 ) were treated with ER niacin/laropiprant 1 g/20 mg for 4 weeks and then the dose was doubled for an additional 8 weeks.

Measurements of fasting lipids, glucose, insulin, and adiponectin were performed at baseline and during the study.

Results.

There were significant ( P < 0.001 ) increases in glucose (9.4 ± 13.1%), insulin (70.2 ± 91.0%), HOMA-IR (87.8 ± 103.9%), and adiponectin (169.3 ± 111.6%).

The increase in adiponectin was significantly associated with increase in glucose ( r = 0.221 , P < 0.05 ) , insulin ( r = 0.184 , P < 0.05 ) , and HOMA-IR ( r = 0.237 , P < 0.01 ) and the association remained significant after adjustment for changes in body weight or body fat mass.

Conclusion.

Treatment with ER niacin/laropiprant led to a significant increase in adiponectin levels but worsening of glucose levels and insulin resistance, and the increase in adiponectin and insulin resistance were correlated suggesting the increase in adiponectin did not ameliorate the deterioration in insulin resistance.

Clinical trial is registered with number on WHO-ICTRP: ChiCTR-ONC-10001038.